Vaccines targeting lethal and multi-resistant bacteria


Discover and develop safe and effective vaccines to overcome infectious challenges threatening global public health


A world free of suffering from infectious diseases

Proxi Biotech offers best in class technology for creating next generation vaccine antigens targeting bacterial infections

Antimicrobial resistance (AMR) is one of the world's most pressing medical problems. More than 700,000 people die each year from infections resistant to antibiotics. By 2050, such infections are expected to kill 10,000,000 people.

Proxi Biotech, an early stage spin-off from Staten Serum Institute, has developed the BID Technology for detoxification of bacterial toxins. BID Technology replaces the conventional cross-reacting agents in the development of new antigens for toxoid-based vaccines that are highly needed to overcome the AMR challenge.


Contact information

Nørre Allé 41

2200 Copenhagen


Copyright 2019 Proxi Biotech All Rights Reserved